Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 5/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059340 | 0.95 | FOLH1 (0.47) | FURINFOLH1GSRDPP8DPP9 | |
| SCHEMBL27164802 | 0.93 | CPB2 (0.45) | FURINFOLH1GSRDPP8DPP9 | |
| SCHEMBL27165073 | 0.93 | CPB2 (0.45) | FURINFOLH1GSRDPP8DPP9 | |
| SCHEMBL28220279 | 0.92 | FURIN (0.43) | FURINFOLH1NOD1 | |
| SCHEMBL31593274 | 0.92 | FURIN (0.47) | FURIN | |
| SCHEMBL28220278 | 0.92 | FURIN (0.43) | FURINFOLH1NOD1 | |
| SCHEMBL29397210 | 0.91 | GSR (0.50) | FOLH1GSRDPP8DPP9DPP7 | |
| SCHEMBL29591176 | 0.91 | FURIN (0.46) | FURINCPB2 | |
| SCHEMBL30997481 | 0.89 | FOLH1 (0.42) | FURINFOLH1CPB2 | |
| SCHEMBL29591590 | 0.89 | CPB2 (0.45) | FURINFOLH1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041740-A1 | SKIN PEEL COMPOSITIONS | GLO PHARMA INC (US) | 2024-02-08 | — | — | US | disclosed |
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | GLO PHARMA INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270635-A1 | METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS | CUTA, GLA, LIPA | FURIN 1030/4885FOLH1 1417/4885GSR 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.